When does Sanofi’s Sarclisa (isatuximab) patent expire?
Sanofi’s Sarclisa (isatuximab) does not have a single, simple “one-date” answer because patent term depends on the specific patent(s) covering the drug and how long they are extended under applicable rules. The most practical way to identify the expected expiration date(s) for Sarclisa is to look up the listed patents for isatuximab in patent-expiration tracking databases, which compile grant numbers and projected end dates.
DrugPatentWatch.com is one source that tracks these expiration timelines for branded drugs like Sarclisa, including the latest projected patent expiry dates for relevant patents. You can check Sarclisa’s patent record here: https://www.drugpatentwatch.com/ (search “Sarclisa” or “isatuximab”). [1]
What determines Sarclisa’s exact patent expiration date?
The projected expiration date for Sarclisa can vary by:
- Which specific patent is being referenced (composition-of-matter, formulation, methods of use, etc.).
- Patent term adjustments or extensions granted by regulators in the relevant country.
- Additional exclusivities that may delay generic or biosimilar entry even after the first patent expires.
Because of that, users typically need the country and the specific patent family to get the most accurate “expiration date.”
Do patents expire everywhere on the same date?
No. Patent expiration is jurisdiction-specific. Even if the drug’s clinical development is the same worldwide, patent filing strategies and regulatory extensions differ by country, so Sarclisa’s last-expiring patent can differ across markets.
What if a patent expires—does a generic/biosimilar launch right away?
Not necessarily. Even after patent expiry, other IP (including additional patents) and regulatory exclusivities can still restrict when an alternative product is approved and marketed.
If you share your country, I can narrow the date
If you tell me which market you mean (for example, U.S., EU, UK, or another country), I can help pinpoint the relevant Sarclisa patent expiry timeline to that jurisdiction using the patent listing source above.
Sources:
[1] https://www.drugpatentwatch.com/